Literature DB >> 15520402

Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers.

J Huang1, S M Domchek, M S Brose, T R Rebbeck, K L Nathanson, B L Weber.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15520402      PMCID： PMC1735609          DOI： 10.1136/jmg.2004.022913

Source DB:  PubMed          Journal:  J Med Genet        ISSN： 0022-2593            Impact factor:   6.318


× No keyword cloud information.
  5 in total

Review 1.  Clinical implications of low-penetrance breast cancer susceptibility alleles.

Authors:  Francis Freisinger; Susan M Domchek
Journal:  Curr Oncol Rep       Date:  2009-01       Impact factor: 5.075

2.  Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts.

Authors:  Daphne W Bell; Sang H Kim; Andrew K Godwin; Taryn A Schiripo; Patricia L Harris; Sara M Haserlat; Doke C R Wahrer; Christopher A Haiman; Mary B Daly; Kristin B Niendorf; Matthew R Smith; Dennis C Sgroi; Judy E Garber; Olufunmilayo I Olopade; Loic Le Marchand; Brian E Henderson; David Altshuler; Daniel A Haber; Matthew L Freedman
Journal:  Int J Cancer       Date:  2007-12-15       Impact factor: 7.396

3.  A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers.

Authors:  Deborah Thompson; Sheila Seal; Mieke Schutte; Lesley McGuffog; Rita Barfoot; Anthony Renwick; Rosalind Eeles; Nayanta Sodha; Richard Houlston; Susan Shanley; Jan Klijn; Marijke Wasielewski; Jenny Chang-Claude; P Andrew Futreal; Barbara L Weber; Katherine L Nathanson; Michael Stratton; Hanne Meijers-Heijboer; Nazneen Rahman; Douglas F Easton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-12       Impact factor: 4.254

Review 4.  CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer.

Authors:  Victoria Hale; Maren Weischer; Jong Y Park
Journal:  Prostate Cancer       Date:  2014-11-06

5.  CHEK2 1100delC in patients with metachronous cancers of the breast and the colorectum.

Authors:  Anna Isinger; Misha Bhat; Ake Borg; Mef Nilbert
Journal:  BMC Cancer       Date:  2006-03-15       Impact factor: 4.430
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.